This site is intended for healthcare professionals

Liquidia receives Complete Response Letter from FDA for LIQ 861 inhalation powder for the treatment of pulmonary arterial hypertension.

Read time: 1 mins
Last updated:26th Nov 2020
Published:26th Nov 2020
Condition: Pulmonary Arterial Hypertension
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest